Drug sensitivity testing of patient-derived bone sarcomas identifies selective kinase inhibitors for patients with refractory disease

Key Points

• This research aims to identify effective treatments for patients with refractory bone sarcomas using drug sensitivity testing.
• Conducted drug sensitivity testing on patient-derived cultures from bone sarcomas.
• Analyzed the behavior of different clones in PDC cultures to observe growth and evolution patterns.
• Investigated the effectiveness of selective kinase inhibitors against the tumors.
• Identified specific kinase inhibitors that showed sensitivity in patient-derived cultures.
• Demonstrated that clonal evolution occurs within the tumor cultures, contributing to treatment resistance.
• Highlighted the potential for rapid identification of effective treatment options for complex tumors.